Find out more about our clinical trials: Read More

Learn More About Our Innovative Biotechnology

Press Releases, Publications, & Videos

Publications
A71D6692-5CFE-4689-B857-C80775B0E4E8

ASCO 2024 AVM0703 Poster #7077: Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immuno-activating AVM0703 with few and mild drug-related adverse effects

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

See a very compelling AVM0703 compassionate use patient story of hope and loving life in Allina Health annual report

Presentation
Group 3

AVM Biotechnology Provides a Solution to Needed Innovation for Cancer Cures

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Biotechnology Selected by the National Cancer Institute to Present at Bio Investor Forum 2023

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

National Cancer Institute Selects AVM Biotechnology as a 2023-2024 Showcase Company

A metastatic esophageal adenocarcinoma patient during his 8th AVM0703 infusion. "OverallI have to say AVM0703 has been the only drug used to tackle my throat cancer since myfirst AVM0703 treatment on Nov 18th Nov 2022. The result has been rewarding with little byway of side effects apart from dull pain emerging 24 hours after treatment periods roundcancer infected upper chest area. This pain seems to last approx 3 hours then fades awayand sometimes repeats again on the second day after treatment. No doubt this pain isAVM0703 at work, targeting the cancer. Thank you all for your advice and guidance, byputting the wellness back into my health again. Thank you to all at AVM Biotechnology."
Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients have been Treated with Immunomodulatory AVM0703 through Expanded Access/Compassionate Use Programs

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

NIH awards AVM Biotechnology SBIR grant to study AVM0703 combined with R-CHOP

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Biotechnology Awarded $2 Million National Cancer Institute SBIR Phase II Grant from the National Institutes of Health to Advance AVM0703 in Cancer

Publications
A71D6692-5CFE-4689-B857-C80775B0E4E8

Acute Supra-pharmacologic Weight-based Dexamethasone (AVM0703), 18 mgs/kg Body Weight, Mobilizes Endogenous Bi-specific Natural Killer T-like Cells Independent of Glucocorticoid Receptor Activation

Publications
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM0703 Mobilization of Endogenous Gamma Delta/Invariant TCR+ Bi-Specific Natural Killer T-like Cells Effective Against Solid Tumors and Blood Cancers

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Presents Poster Highlighting the Effects of AVM0703 at the 2022 ASCO Annual Meeting

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Biotechnology Founder and CSO to Present Company Information and Clinical Trial Progress at Life Science Innovation Northwest

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes

Publications
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM0703 Tumor Debulking Enhances Cy/Flu Efficacy

Publications
A71D6692-5CFE-4689-B857-C80775B0E4E8

Very-High Dose Dexamethasone Mobilizes Endogenous Bi-Specific Gamma Delta+ NKT Cells

Presentation
Group 3

Oncology Tube Profiles Acceleration of Dosing in AVM NHL Clinical Trial

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

FDA Approves Accelerated Dosing in NHL/Leukemia Clinical Trial

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients dosed with AVM0703

AVM Biotech
Presentation
Group 3

Theresa Deisher Speaks at ESWI Influenza Conference

Publications
A71D6692-5CFE-4689-B857-C80775B0E4E8

Pharma’s Almanac Features AVM0703

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Biotechnology CEO/CSO Selected to Speak at ESWI Conference in Novel and Outstanding Discoveries Track

AVM Biotech
Presentation
Group 3

What is AVM0703? Find Out!

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

President Receives Dexamethasone Treatment

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Receives FDA Permission for Clinical Trials in COVID-19/ARDS

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Expands Executive Team, Appoints Janet R. Rea COO

AVM Biotech
Presentation
Group 3

Amplifying Scientific Innovation Podcast

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM’s Dexamethasone Formulation Has Potential For Greater Impact Than Oxford’s

AVM Biotech
Presentation
Group 3

Oxford/AVM’s potential COVID-19 Treatment Featured on KOMO News

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Awarded SBIR Grant From National Cancer Institute

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

FDA Approves AVM0703 Clinical Trials in R/R Non-Hodgkins Lymphoma

AVM Biotech
Presentation
Group 3

Cavendish Global 2020

Publications
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM0703, a New Treatment Option for Lymphoma Patients

Unleashing Human Immune Potential